Highlights of weekly biotech stock moves

Algeta ASA (OSE:ALGETA) gained NOK16 to NOK220 last week after FDA approved an NDA from partner Bayer AG (Xetra:BAYN) for Xofigo radium-223 dichloride to treat castration-resistant prostate cancer (CRPC) in patients with symptomatic bone metastases. Xofigo is under review in Europe.

Biogen Idec Inc. (NASDAQ:BIIB) was up $13.63 to $226.85 last week after partner Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit submitted regulatory applications to FDA and EMA for obinutuzumab (GA101) to treat chronic lymphocytic leukemia (CLL). The submissions were based on positive Phase III data showing obinutuzumab plus chlorambucil chemotherapy met the primary endpoint of improving median progression-free survival (PFS) vs. chlorambucil alone in Stage 1a of the Phase III CLL11 trial (see B16). ...